| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Abel Robert Lorne | EVP, Chief Scientific Officer, Platform | C/O SCHRODINGER, INC.,, 1540 BROADWAY, 24TH FLOOR, NEW YORK | /s/ Donald Shum, as attorney-in-fact for Robert Lorne Abel | 11 Feb 2026 | 0001798179 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SDGR | Common Stock | Sale | $16,617 | -1,230 | -6% | $13.51 | 19,385 | 09 Feb 2026 | Direct | F1, F2 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units ("RSUs"). The sale does not represent a discretionary trade by the reporting person. |
| F2 | Includes 15,137 unvested RSUs. |
EVP, Chief Scientific Officer, Platform